Point-of-care (POC) diagnostics now operates routinely outside the central laboratory. Decentralized infrastructure is established across most regulated markets, and clinical demand for rapid, near-patient answers continues to accelerate. The binding constraint today is no longer feasibility but commercialization: which in vitro diagnostic (IVD) platforms can scale from pilot to production, support multiplexed panels across indications, and navigate demanding regulatory regimes without rework.
Multiplex assays, which detect multiple targets from one sample in one workflow, are the clinical default for syndromic indications. Yet many multiplex platforms that achieve clinical validation never reach commercial volume. The barriers are consistent: assay-to-manufacturing misalignment, cartridge inconsistency at scale, fragile reagent supply chains, late-stage regulatory discovery, and architectural rigidity that resists panel expansion. The root cause is monolithic design, where hardware, fluidics, firmware, and software are tightly coupled and co-validated as one product.
This white paper examines the modular alternative. Modular multiplex architectures separate the device into independently validated subsystems, allowing IVD companies to extend their platform across new panels, indications, and geographies without redesigning what works. Shorter development cycles, stable bills of materials, regulatory leverage through platform master files, and lower total cost of ownership accumulate across the platform’s commercial lifetime. The most successful programs treat their platform as a reusable asset and consolidate the manufacturing stack under one accountable team.
Diagnostics has moved past the question of whether testing can be performed at the point of care. Decentralized testing is established across most regulated markets. The unresolved question now is which platforms are scalable, multiplexed, and manufacturable enough to actually reach patients at volume.
The in vitro diagnostics (IVD) market has fragmented into three architectural categories: single-use cartridges built around one indication, syndromic systems with fixed multiplex configurations, and modular platforms designed for an expanding catalog of assays on shared infrastructure. The architectural choice determines unit economics, regulatory pathway, supply chain exposure, and time-to-next-panel. Choosing wrong means stalled commercialization, BOM instability, and regulatory rework.
Each category serves a legitimate use case. The choice is consequential because the constraints that suit one architecture often disqualify the others, and programs that select before clarifying their commercial roadmap typically pay for that misalignment in the second or third panel.
Four converging pressures have driven the shift to near-patient diagnostics and continue to shape demand.
Per MarketsandMarkets, the global POC diagnostics market is projected to reach USD 22.63 billion by 2029, expanding at a CAGR of 8.5 percent from 2024 to 2029. Growth is concentrated in molecular and multiplex segments rather than legacy lateral-flow formats.
Multiplex testing means detecting multiple analytes (nucleic acid targets, antigens, or antibodies) from one sample in one workflow. In clinical practice, this typically takes the form of syndromic testing, where a panel of likely pathogens is screened for a given clinical presentation. Common categories include respiratory, gastrointestinal, STI, central nervous system, and sepsis panels.
Several enabling technologies have matured concurrently:
Before evaluating any platform, IVD teams should pressure-test the architecture against five criteria. Strength in one does not compensate for weakness in another.
6.1. Sample-to-Answer Integration
The platform must handle sample preparation, reagent stability, chemistry, and result interpretation in one closed workflow. Open systems that depend on operator pipetting reintroduce the contamination and variability risks POC testing exists to eliminate.
6.2. Cartridge and Microfluidic Reproducibility
Microfluidic designs that work in prototype frequently fail at production scale. Channel tolerances, surface-energy variation across injection-molded lots, and reagent deposition consistency all influence assay performance. Fluidic design must be validated against realistic high-volume manufacturing tolerances.
6.3. Analytical Sensitivity Under Multiplex Load
Cross-reactivity, primer-dimer formation, and signal interference rise non-linearly with each added target. A four-plex is rarely four times harder to validate than single-plex; difficulty scales with combinatorial off-target interactions. Robust platforms manage this through careful primer and probe design, internal controls, and validated signal deconvolution.
6.4. Embedded Intelligence
Real-time signal processing, firmware reliability, and connectivity are no longer optional. End-users expect results in electronic health records (EHRs) and laboratory information systems. This requires software developed under IEC 62304, cybersecurity aligned with FDA premarket guidance, and update mechanisms that preserve the validated state.
6.5. Design for Manufacturing (DFM)
DFM gaps are a frequent contributor to scaling difficulties. An elegant design requiring custom tooling, low-yield components, or specialized assembly will not survive commercial economics. Manufacturability must be a design input from concept stage.
First-generation POC multiplex platforms were monolithic: hardware, fluidics, firmware, optics, and user interface tightly coupled and co-validated. That rigidity is now the principal constraint on commercial expansion.
7.1. The Problem with Monolithic Systems
Monolithic platforms impose expensive redesigns for any new panel, sample type, or readout. Component obsolescence in any subsystem can trigger requalification of the entire device. Single-source dependencies expose programs to disproportionate risk, and submissions for new panels repeat substantial portions of the original validation.
7.2. Modularity in Practice
A modular platform separates the device into independently validated layers: reusable hardware chassis, firmware and operating system, fluidic and cartridge interface, detection module, user interface, and connectivity. Defined interfaces allow one layer to evolve without redesigning the others.
7.3. The Advantages Modular Platforms Unlock
The trade-offs between architectures are summarized below.
|
Dimension |
Monolithic |
Modular |
|
Development Cycle |
Substantially longer per new panel |
Markedly shorter per new panel |
|
Customization Effort |
High; often requires full redesign |
Contained to affected layer(s) |
|
BOM Stability |
Vulnerable to single-source obsolescence |
Pre-qualified, second-sourced components |
|
Regulatory Rework |
Substantial revalidation per submission |
Leverages platform master file |
|
Time-to-next-panel |
Years |
Quarters |
Across IVD programs, the same readiness gaps recur between clinical validation and reliable commercial supply. Closing them as part of design, rather than at transfer, is what distinguishes platforms that scale from those that stall.
These are most effectively treated as design inputs rather than transfer-phase considerations. Manufacturing readiness and integrated QARA function as the connective tissue between clinical performance and commercial viability.
Multiplex IVD platforms navigate overlapping frameworks. The U.S. Food and Drug Administration (FDA) regulates most multiplex devices under 510(k), with higher-risk indications routed through De Novo or Premarket Approval (PMA). The European Union In Vitro Diagnostic Regulation (IVDR) 2017/746, fully applicable from May 2022 with extended transition timelines under Regulation (EU) 2024/1860, imposes substantially heightened performance evidence requirements under Annex I and Annex II compared to the prior IVDD. [4] In India, the Central Drugs Standard Control Organisation (CDSCO) regulates IVDs under the Medical Devices Rules 2017. Quality systems anchor globally to ISO 13485:2016, and in the US, Clinical Laboratory Improvement Amendments (CLIA) waiver status is a prerequisite for most decentralized deployments.
Multiplex-specific validation deserves particular attention. Analytical validation must demonstrate performance across every target, every co-infection combination, and the full range of specimen types, since cross-reactivity panels expand combinatorially. Software validation under IEC 62304, cybersecurity aligned with the FDA’s current premarket cybersecurity guidance (most recently reissued in February 2026 to align with the new Quality Management System Regulation), and risk management under ISO 14971 are not optional. [5] QARA embedded from concept stage, rather than engaged at submission, is the difference between predictable approvals and last-minute discovery.
Scaling a multiplex IVD from pilot to commercial volume requires capabilities that few standalone vendors provide end-to-end:
Fragmented vendor stacks create handoff inefficiencies that compound at scale. End-to-end contract design and manufacturing organization (CDMO) partnerships consolidate these under one quality management system, shortening the loop between manufacturing learnings and design refinements.
12.1. AI-Enabled Interpretation
Machine learning models embedded in IVDs support predictive triaging, decision support, and automated quality control. The regulatory burden is material: development must align with the IMDRF Good Machine Learning Practice guiding principles (N88 FINAL:2025), [6] adaptive models require Predetermined Change Control Plans per the FDA’s December 2024 final guidance, [7] and devices placed on the EU market are subject to the EU AI Act (Regulation (EU) 2024/1689), under which AI systems that are safety components of, or are themselves, medical devices and IVDs requiring third-party conformity assessment are classified as high-risk; full compliance obligations for these systems apply from August 2, 2027. [8]
12.2. Connected Diagnostic Ecosystems
Cloud reporting, remote monitoring, and EHR interoperability are becoming table-stakes, placing demands on device software: secure communication, HL7 FHIR-compliant data exchange, and uptime expectations more familiar to enterprise software than medical devices.
12.3. Digital Microfluidics and Handheld Molecular Platforms
Electrowetting-on-dielectric and droplet-based digital microfluidics enable programmable workflows previously requiring complex pumping infrastructure. Combined with miniaturized optics, they are pushing molecular diagnostics into truly handheld form factors. Manufacturability remains non-trivial, particularly dielectric coating uniformity and electrode patterning at scale.
Two anonymized industry examples illustrate what becomes achievable when architecture, DFM, and QARA align from concept stage.
Point-of-care screening IVD: A modular multiplex platform for infectious disease screening achieved a 41 percent BOM reduction against the originating prototype and scaled from pilot to an 11-fold pilot volume increase on the same engineering and manufacturing team. Full CDSCO registration support and manufacturing readiness were achieved within the planned timeline of design freeze.
Digital microfluidic diagnostic platform: A programmable digital microfluidic platform supporting multiple assay configurations completed development-to-manufacturing transition 45 percent faster than the originating company’s baseline and reached full operational readiness in under six months, enabled by reusable hardware and firmware subsystems and a co-developed manufacturing process.
The common thread: architecture decisions at concept stage, which included committing to modular subsystems, embedding manufacturing engineers in design teams, and engaging QARA before the first design review, determined the commercial outcome. Clinical performance was necessary but not sufficient.
Architecture selection is a function of program constraints rather than generic prescription.
Syrma Johari MedTech (SJML) is a working example of the platform-accelerator philosophy in execution. The company operates 16 manufacturing sites and 4 design centers across India, the US, and Europe, with modular reference architectures spanning in vitro diagnostics, pain management, and aesthetics; in-house PCBA; medical-grade plastics manufacturing, including injection molding, insert and overmolding, micromolding, and liquid silicone rubber (LSR) molding; ISO Class 7 and Class 8 cleanrooms; and integrated QARA covering FDA, EU MDR/IVDR, CDSCO, and MDSAP submission pathways under a single quality system. This approach has already produced measurable outcomes: bill-of-materials reductions exceeding 40%, production readiness in under six months, and seamless manufacturing scale-ups by the original engineering team without any redesigns. Its work with diagnostics innovators includes Hemex Health, taking assay development and manufacturing scale-up from prototype to global deployment, and Intelligent Bio Solutions, whose reader shipments have been publicly confirmed to meet ISO 13485 and MDSAP standards. SJML was recognized with the MedTech CDMO of the Year, Diagnostics and IVD award at the National Diagnostics Forum and Awards 2026.
The next decade of POC diagnostics will be won by teams who treat their platform as a reusable asset rather than a single product, who engineer manufacturability and regulatory evidence into the architecture from concept stage, and who close the loop between design and manufacturing within a single accountable team.
Modular multiplex architecture is how that gets done. The clinical urgency for decentralized diagnostics is established. The technologies are mature. The remaining gap is execution discipline across architecture, manufacturing, and QARA, and that gap is bridgeable.
For MedTech teams evaluating this shift, SJML’s IVD team brings integrated design, manufacturing, and QARA together under one roof. Programs typically begin with a design-for-manufacturing review to identify where an existing device or early-stage concept stands to benefit most from a modular, reusable architecture. Learn more about Diagnostics.
16.1. What is the difference between multiplex and syndromic testing?
Multiplex is the technical capability of detecting multiple analytes from one sample in one workflow. Syndromic testing is a specific clinical use of that capability, where a panel is built around the pathogens most likely to cause a defined clinical presentation, such as a respiratory panel that screens for influenza, RSV, and COVID-19 together instead of ordering separate tests. All syndromic tests are multiplex; not all multiplex tests are syndromic.
16.2. How does modular architecture shorten regulatory timelines?
Modular architectures support a platform master file that downstream panels reference. New panels submit assay-specific data without re-establishing the underlying hardware, firmware, or software, which is the most evidence-intensive portion of a submission.
16.3. Is microfluidics worth the manufacturing complexity?
For sample-to-answer integration with small volumes and contamination-sensitive chemistries, microfluidics remains dominant. The trade-off is favorable when assay sensitivity and workflow closure are clinically essential.
16.4. What is the risk of locking into a modular platform from a single CDMO?
A legitimate concern, best addressed in commercial terms: source-code escrow, design history file ownership reverting to the originating company, dual-source component qualification, and contractual rights to transfer manufacturing. SJML structures these protections into every platform engagement by default, rather than as a negotiated exception. With these protections in place, consolidated accountability typically outweighs diversification risk.
16.5. How early should QARA be involved in IVD development?
Before the first design input is documented. Quality and regulatory considerations shape decisions about intended use, classification, and evidence strategy that are extraordinarily expensive to revisit later.
16.6. Can a modular platform serve both infectious disease and oncology panels?
Yes, where chemistry and detection are compatible. A platform built around nucleic acid amplification with fluorescent multiplex readout can support infectious disease, oncology mutation, and pharmacogenomic panels with chemistry-level differences rather than platform-level redesign.
16.7. What is the typical development-to-manufacturing timeline for a POC IVD?
Timelines vary substantially with regulatory pathway, assay complexity, and starting architecture. Greenfield monolithic platforms generally take several years from concept to first commercial shipment. Modular platforms leveraging a pre-validated accelerator architecture can compress the first panel meaningfully, with subsequent panels reaching market faster as the platform investment is amortized across the portfolio. SJML’s own diagnostics programs illustrate this range, including a digital microfluidic platform that reached full operational readiness in under six months, a 45 percent faster development-to-manufacturing transition than the originating baseline.
